Singapore, March 27 -- The Health Sciences Authority received information related to the study titled 'A Single-Arm, Phase IIIb Global, Multi-center Study of Durvalumab in Combination with Tremelimumab and Lenvatinib Given Concurrently with Locoregional Therapy in Participants with Locoregional Hepatocellular Carcinoma (EMERALD-CURE)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National Cancer Centre
National University Hospital
Trial Status: Not Yet Recruiting
Principal Investigator(s):
Dr David Tai
Dr Yong Wei Peng
Published by HT Digital Content Services with permission from Health Daily Digest....